H.Res. 1041House117th Congress (2021-2023)In Committee

Supporting the designation of July 20, 2022, as "Glioblastoma Awareness Day".

Introduced April 6, 2022

Legislative Activity

Stay on top of the latest movement without scrolling through every action

2 earlier actions
HouseCommittee Latest Action

Referred to the Subcommittee on Health.

April 7, 2022

View full timeline
HouseIntro Referral

Introduced in House

April 6, 2022

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

April 6, 2022

HouseCommittee

Referred to the Subcommittee on Health.

April 7, 2022

Floor Debate

4 members

What members said about H.Res. 1041 on the floor

4 Democrats
Brendan F. Boyle
Rep. Brendan F. BoyleD-PA-2 · Sep 28, 2021

Madam Speaker, I thank my good friend and colleague, the gentleman from Colorado (Mr. Neguse), who does a wonderful job, as well as my friend, my fellow Pennsylvanian, Mr. Cartwright. I am glad to be…

Joe Neguse
Rep. Joe NeguseD-CO-2 · Sep 28, 2021

Madam Speaker, I ask unanimous consent that all Members have 5 legislative days to revise and extend their remarks and include extraneous material on the subject of my Special Order. Madam Speaker,…

Matt Cartwright
Rep. Matt CartwrightD-PA-8 · Sep 28, 2021

Madam Speaker, I thank the distinguished gentleman from Colorado for yielding. It is true. Today, in the Congress, the Treasury Secretary of the United States, Janet Yellen, testified that we will…

Sheila Jackson Lee
Rep. Sheila Jackson LeeD-TX-18 · Sep 28, 2021

Madam Speaker, I am most grateful for the opportunity to join the gentleman from Colorado, the gentleman from Pennsylvania, and the gentleman from Pennsylvania. I have just finished with a conference…

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued April 6, 2022

IV

117th CONGRESS

2d Session

H. RES. 1041

IN THE HOUSE OF REPRESENTATIVES

April 6, 2022

Mr. Mast (for himself, Ms. Schakowsky, Mr. Gallagher, Mr. Langevin, and Mr. Trone) submitted the following resolution; which was referred to the Committee on Energy and Commerce

RESOLUTION

Supporting the designation of July 20, 2022, as Glioblastoma Awareness Day.

Whereas approximately 13,460 new cases of glioblastoma will be diagnosed in the United States in 2022;

Whereas glioblastoma is—

(1)

the most common malignant brain tumor, accounting for approximately 1/2 of all primary malignant brain tumors; and

(2)

the most aggressive, complex, difficult to treat, and deadly type of brain tumor;

Whereas it is estimated that more than 10,000 individuals in the United States will succumb to glioblastoma each year;

Whereas the 5-year survival rate for glioblastoma patients is only 6.8 percent, and the median length of survival for glioblastoma patients is only 8 months;

Whereas glioblastoma is described as a disease that affects the essence of self, as the treatment and removal of glioblastoma presents significant challenges due to the uniquely complex and fragile nature of the brain, the primary organ in the human body that controls not only cognitive ability, but also the actions of every organ and limb;

Whereas patients and caregivers play a critical role in furthering research for glioblastoma;

Whereas, relative to other types of cancers, brain cancer patients pay the second highest out-of-pocket costs for medical services in both the initial and end-of life phases of care;

Whereas, although research advances may fuel the development of new treatments for glioblastoma, challenging obstacles to accelerating progress toward new treatments for glioblastoma remain, and there are no screening or early detection methods;

Whereas, in 2021, the World Health Organization reclassified brain tumors and made significant changes to the molecular characteristics of a glioblastoma diagnosis, necessitating critical biomarker testing for patients suspected of having a possible glioblastoma;

Whereas, although glioblastoma was first described in medical and scientific literature in the 1920s, and despite its devastating prognosis, only 4 drugs and 1 medical device have been approved by the Food and Drug Administration to treat glioblastoma since the 1920s, and the mortality rates associated with glioblastoma have changed little during the past 30 years;

Whereas, in 2020, the National Cancer Institute established the Glioblastoma Therapeutics Network (referred to in this preamble as GTN), as part of a national infrastructure to enhance and support the discovery and development of glioblastoma therapies available for multi-institutional GTN teams to drive therapeutic agents through pre-clinical studies and early-phase clinical trials, which are necessary to rapidly evaluate potential treatments to advance toward cures and improved quality of life; and

Whereas there is a need for greater public awareness of glioblastoma, including awareness of both—

(1)

the urgent unmet medical needs of glioblastoma patients; and

(2)

the opportunities for research of, and treatment advances for, glioblastoma: Now, therefore, be it

That the House of Representatives—

(1)

supports the designation of Glioblastoma Awareness Day;

(2)

encourages increased public awareness of glioblastoma;

(3)

honors the individuals who have died from glioblastoma, a devastating disease, or are currently living with it;

(4)

supports efforts to develop better treatments for glioblastoma that will improve the long-term prognosis for, and the quality of life of, individuals diagnosed with the disease;

(5)

recognizes the importance of molecular biomarker testing to the diagnosis and treatment of glioblastoma;

(6)

expresses support for the individuals who are battling brain tumors, as well as the families, friends, and caregivers of those individuals;

(7)

urges a collaborative approach to brain tumor research among governmental, private, and nonprofit organizations, which is a promising means of advancing the understanding and treatment of glioblastoma; and

(8)

encourages continued investments in glioblastoma research and treatments, including through the Glioblastoma Therapeutics Network and other existing brain tumor research resources.